Glycomimetics is an HSCT Vertical Play That Could Change Hematology
Bullish Free Articles
How We Believe The GLYC Story Will Play Out.
After Danny and I did deeper digging, while we think secondary AML will hit, but the overall NCI denovo AML topline data will not be stat-sig. However, we also think the company will bury this as they don’t have to…
GlycoMimetics is a Bigger Deal Than Most Realize
I’ll get to the point. This company is a platform story, not just AML. Additionally, if both NCI and Company sponsored AML trials prove-out, the peak sales are close to $1B, not the $300M most wrongly calculate. why? Uproleselan is…
Why Glycomimentics is Running Up Hard+ Discord Chat Info.
I wanted to add some commentary on Glycomimetics (GLYC) as I own shares – all of them under 1 dollar as I said I would buy once prior management was removed. The prior management well, mismanaged the company’s trials -…
FPRX Article Preview
Summary Identifying undervalued developmental Biotech companies that have the potential for a turn-around story, swing trade and/or investment can often times be rewarding. Five Prime Pharma could be such a turn-around story with a deep pipeline and recent form 13D…
Immunotherapy Explained Part 3 – In Relation To Affimed
Immunotherapy Explained Part 2 – In Relation To Affimed. In part 3 here we explain and expand in the science of Immunotherapy and explain in part how $AFMD is differentiated, explain the $MRK Keytruda/AFM 13 trial plus a lot more.…
Relypsa: How Bulls and Bears are Both Right (Archived)
You may be thinking; how can the bull and bear case on Relypsa (NASDAQ:RLYP) both be right? Before we get to this, let’s review in brief what’s been surrounding the company over the last few months. In October of last…
Affimed Science Explained – Technical Breakdown
Danny has explained Affimed’s science below, which for some may be a bit complex. Tomorrow, I will look to break down the technical explanations in more simpler terms — this is a big reason many up and coming TRUE potential…
The Fairway Group Long Swing Trade Thesis – Earnings Play/Short Cover
The Fairway Group (FWM) is set to report earnings after the bell on May 26th, 2015. Immediately before the last earnings report, the stock made a nice run up and continued to run to over $7, before being re shorted…
Fairway Group Likely To Beat On Bottom Line EPS – Strong Acquisition Candidate
Summary On May 28th, 2015, Fairway is scheduled to report its earnings from its last quarter. During the last quarter, the EURO dollar weakened substantially while the dollar gained. This factor has likely been over looked by the analysts covering…